Literature DB >> 2949056

Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro.

J Arnt, J Hyttel.   

Abstract

The effects of 30 dopamine (DA) antagonists, including 4 as stereoisomeric pairs, on circling behaviour induced by the D-1 agonist SKF 38393 and the D-2 agonist pergolide in rats with unilateral 6-hydroxy-DA lesions have been studied. SKF 38393-induced circling was selectively blocked by the specific D-1 antagonists SCH 23390 and SKF 83566, and was furthermore blocked by other DA antagonists with potencies correlating to their affinities to D-1 receptors labelled by 3H-SCH 23390 in vitro. Pergolide-antagonistic potencies in contrast correlated to affinities to D-2 receptors labelled by 3H-spiperone in vitro. Pergolide-induced circling was selectively blocked by the specific D-2 antagonists in the benzamide series. No interaction between D-1 and D-2 antagonists was observed in combination experiments with SCH 23390 and YM 09151-2 in both circling models. Among other reference neurotransmitter antagonists acting on alpha- and beta-adrenoceptors, histamine, serotonin and muscarinic receptors, only the alpha 1-adrenoceptor antagonist prazosin was effective in high doses. In contrast, the alpha 2- and beta-adrenoceptor agonists clonidine and clenbuterol as well as the muscarinic agonist RS 86 inhibited circling induced by SKF 38393 as well as pergolide. The 5-HT1A agonist 8-OHDPAT inhibited pergolide-induced circling only. It is concluded that these two behavioural models are selective in vivo measures of relative D-1 and D-2 receptor activity of DA antagonists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949056     DOI: 10.1007/bf01243350

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  32 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.

Authors:  M Terai; S Usuda; I Kuroiwa; O Noshiro; H Maeno
Journal:  Jpn J Pharmacol       Date:  1983-08

3.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

4.  SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.

Authors:  S Boyce; E Kelly; A Davis; S Fleminger; P Jenner; C D Marsden
Journal:  Biochem Pharmacol       Date:  1985-05-15       Impact factor: 5.858

5.  beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses.

Authors:  P J Cowen; D G Grahame-Smith; A R Green; D J Heal
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

6.  Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.

Authors:  R A Glennon; R Young; J A Rosecrans
Journal:  Eur J Pharmacol       Date:  1983-07-22       Impact factor: 4.432

7.  Discriminative stimulus properties of the serotonin agonist 1-(3-trifluoromethylphenyl)piperazine (TFMPP).

Authors:  R A Glennon; J D McKenney; R Young
Journal:  Life Sci       Date:  1984-10-01       Impact factor: 5.037

8.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

9.  Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions.

Authors:  J Arnt
Journal:  Life Sci       Date:  1985-08-26       Impact factor: 5.037

10.  The central effects of a novel dopamine agonist.

Authors:  P E Setler; H M Sarau; C L Zirkle; H L Saunders
Journal:  Eur J Pharmacol       Date:  1978-08-15       Impact factor: 4.432

View more
  7 in total

1.  The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae.

Authors:  John Chen; Roshni Patel; Theodore C Friedman; Kevin S Jones
Journal:  Int J Comp Psychol       Date:  2010

2.  Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 4.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

Authors:  A M Deveney; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions.

Authors:  J Hyttel; J Arnt
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213.

Authors:  S A Daly; J L Waddington
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.